Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Recursion Pharmaceuticals announces collaboration with Roche, Genentech » 07:56
12/07/21
12/07
07:56
12/07/21
07:56
RXRX

Recursion Pharmaceuticals

$18.48 /

+0.67 (+3.76%)

, RHHBY

Roche

$49.73 /

+0.38 (+0.77%)

Recursion (RXRX)…

Recursion (RXRX) announced a transformational collaboration with Roche (RHHBY) and Genentech, a member of the Roche Group. Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well as in an oncology indication. Under the terms of the agreement, Recursion will receive an upfront payment of $150M and is eligible for additional performance-based research milestones. Under the collaboration, Roche and Genentech may initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300M in development, commercialization and net sales milestones for Recursion, as well as tiered royalties on net sales.

ShowHide Related Items >><<
RXRX Recursion Pharmaceuticals
$18.48 /

+0.67 (+3.76%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

RXRX Recursion Pharmaceuticals
$18.48 /

+0.67 (+3.76%)

09/21/21 Berenberg
Recursion Pharmaceuticals initiated with a Buy at Berenberg
05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

04:41 Today Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
RXRX Recursion Pharmaceuticals
$18.48 /

+0.67 (+3.76%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

  • 16
    Apr
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

Hot Stocks
Roche's Actemra/RoActemra approved by EC for patients with severe COVID-19 » 07:33
12/07/21
12/07
07:33
12/07/21
07:33
RHHBY

Roche

$49.73 /

+0.38 (+0.77%)

Roche announced that the…

Roche announced that the European Commission has extended the marketing authorization for Actemra/RoActemra to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. "This decision comes just hours after the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use, reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency," Roche stated.

ShowHide Related Items >><<
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

04:41 Today Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

Hot Stocks
MeiraGTx announces preliminary data from AQUAx Phase 1 trial of AAV-hAQP1 » 07:17
12/07/21
12/07
07:17
12/07/21
07:17
MGTX

MeiraGTx

$17.00 /

-0.55 (-3.13%)

MeiraGTx announced…

MeiraGTx announced positive preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia, RIX. Study Design and Safety Update in the Phase 1 AQUAx Trial of AAV-hAPQ1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia. AQUAx is an open label, multi-center, dose escalation study of a single administration of AAV-hAQP1 to one or both parotid glands in patients with radiation-induced salivary hypofunction and xerostomia. McMaster Global Rate of Change PRO measure results: 6 of the 7 participants who reached the Day 90 assessment reported their symptoms of dry mouth as better following treatment; All 6 of these participants rated changes in xerostomia scores that were important or very important to the participant; 3 participants rated the change in xerostomia symptoms with the highest level of improvement; Improvement in xerostomia symptoms persisted through 1 year in two of the patients who reached Day 360; Participant 1-1 has just reached the 24-month assessment and the highest possible score of 7 was maintained; Participant 2-1 reported no improvement and was the only one of the 7 participants who had no saliva production at baseline; No participant reported a worsening of xerostomia symptoms at any time point. Xerostomia Questionnaire PRO measure results: 6 of 7 participants reaching the Day 90 assessment reported decreases in disease burden of 10 points or more on the XQ; more dramatic reductions of 19, 25, 26, and 41 points were reported by 4 of 7 participants at Day 90; In the participants who completed visits at Day 180 and 360, scores continued to improve or were stable at these later timepoints; One participant reported complete resolution of symptoms at Day 360 following treatment with no symptoms of xerostomia, and has maintained the same score of 0 following the 24 month assessment. Phase 2 Study Plans: Based on the safety and efficacy profile of AAV2-hAQP1 in the AQUAx Phase 1 study and regulatory precedent, the Company intends to initiate a randomized, double-blind, placebo-controlled Phase 2 study evaluating two active doses of AAV2-hAQP1 in the second half of 2022. The change from baseline to 12-months in the McMaster Global Rate of Change questionnaire is expected to be the study's primary efficacy endpoint. Grade 2/3 Radiation-Induced Xerostomia unmet medical need and market size: There are currently 170,000 patients in the U.S. with grade 2/3 RIX two or more years out from successful radiation treatment for head and neck cancer, and an estimated 5,000 to 10,000 new patients per year in the U.S. Current treatment options for RIX are few and are of limited benefit.

ShowHide Related Items >><<
MGTX MeiraGTx
$17.00 /

-0.55 (-3.13%)

MGTX MeiraGTx
$17.00 /

-0.55 (-3.13%)

08/11/21 Piper Sandler
Piper remains buyer of MeiraGTx 'into $40 range' after 'quiet' Q2
07/09/21 Chardan
MeiraGTx coverage transferred at Chardan
04/28/21 Piper Sandler
MeiraGTx should be bought into the $40 range, says Piper Sandler
02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
MGTX MeiraGTx
$17.00 /

-0.55 (-3.13%)

MGTX MeiraGTx
$17.00 /

-0.55 (-3.13%)

Downgrade
AstraZeneca downgraded to Hold from Buy at Jefferies » 04:41
12/07/21
12/07
04:41
12/07/21
04:41
AZN

AstraZeneca

$55.40 /

+1.155 (+2.13%)

, RHHBY

Roche

$49.73 /

+0.38 (+0.77%)

Jefferies analyst Peter…

Jefferies analyst Peter Welford downgraded AstraZeneca (AZN) to Hold from Buy with a 9,100 GBp price target. The analyst remains positive on the European pharma sector but says AstraZeneca has a "relative scarcity" of significant 2022 pipeline catalysts and sentiment risk if its CEO steps aside. Welford names Roche (RHHBY) his top sector pick heading into 2022.

ShowHide Related Items >><<
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

AZN AstraZeneca
$55.40 /

+1.155 (+2.13%)

AZN AstraZeneca
$55.40 /

+1.155 (+2.13%)

12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

AZN AstraZeneca
$55.40 /

+1.155 (+2.13%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

AZN AstraZeneca
$55.40 /

+1.155 (+2.13%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

AZN AstraZeneca
$55.40 /

+1.155 (+2.13%)

AZN AstraZeneca
$55.40 /

+1.155 (+2.13%)

Yesterday
Periodicals
Novartis at work on pan-coronavirus oral treatment, Reuters reports » 12:05
12/06/21
12/06
12:05
12/06/21
12:05
NVS

Novartis

$80.42 /

+0.43 (+0.54%)

Novartis is working on a…

Novartis is working on a pill that could work broadly against coronaviruses, not just the one that causes COVID-19, CEO Vas Narasimhan told Reuters, Pushkala Aripaka reports. In an interview following his recent presentation at Total Health last week, Narasimhan said that "I think we as a sector have collaborated extremely well to ultimately be the industry that enabled this pandemic over time to eventually be under control." Reference Link

ShowHide Related Items >><<
NVS Novartis
$80.42 /

+0.43 (+0.54%)

NVS Novartis
$80.42 /

+0.43 (+0.54%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
NVS Novartis
$80.42 /

+0.43 (+0.54%)

NVS Novartis
$80.42 /

+0.43 (+0.54%)

NVS Novartis
$80.42 /

+0.43 (+0.54%)

NVS Novartis
$80.42 /

+0.43 (+0.54%)

Hot Stocks
Roche completes repurchase of shares from Novartis » 11:42
12/06/21
12/06
11:42
12/06/21
11:42
RHHBY

Roche

$49.35 /

-0.165 (-0.33%)

, NVS

Novartis

$80.69 /

+0.695 (+0.87%)

Roche (RHHBY) announced…

Roche (RHHBY) announced that it completed the repurchase of Roche shares that had been held by Novartis (NVS). On November 4, Roche and Novartis had announced this repurchase. In accordance with the respective resolution of the Extraordinary General Meeting of November 26, the 53,309,000 shares have now been repurchased by Roche and the corresponding consideration has been transferred to Novartis. The repurchased shares will be cancelled upon completion of the corresponding procedure. As previously announced, the transaction does not change the communicated outlook for the full year. Roche expects a mid-single-digit sales growth at constant exchange rates. Core EPS growth at constant exchange rates is targeted to be broadly in line with sales growth. Furthermore, Roche is aiming at increasing the dividend in Swiss francs also for 2021. Christoph Franz, Chairman of the Board of Directors of Roche, said: "With this transaction, we regain full strategic flexibility without compromising our operational scope of action. Rating agencies have confirmed the high quality of our ratings. On the basis of an unchanged dividend policy, all holders of Roche equity securities will benefit from the repurchase and the resolved capital reduction by cancellation of the repurchased shares and the earnings accretion resulting therefrom."

ShowHide Related Items >><<
RHHBY Roche
$49.35 /

-0.165 (-0.33%)

NVS Novartis
$80.69 /

+0.695 (+0.87%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
NVS Novartis
$80.69 /

+0.695 (+0.87%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
RHHBY Roche
$49.35 /

-0.165 (-0.33%)

NVS Novartis
$80.69 /

+0.695 (+0.87%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

NVS Novartis
$80.69 /

+0.695 (+0.87%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

NVS Novartis
$80.69 /

+0.695 (+0.87%)

NVS Novartis
$80.69 /

+0.695 (+0.87%)

Hot Stocks
Roche says CHMP recommends EU approval of Actemra/RoActemra for severe COVID-19 » 09:35
12/06/21
12/06
09:35
12/06/21
09:35
RHHBY

Roche

$49.35 /

-0.165 (-0.33%)

Roche announced that the…

Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended extending the marketing authorisation for Actemra/RoActemra to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future, Roche said.

ShowHide Related Items >><<
RHHBY Roche
$49.35 /

-0.165 (-0.33%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
RHHBY Roche
$49.35 /

-0.165 (-0.33%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

Hot Stocks
Roche to launch SARS-CoV-2 and Flu A/B rapid antigen test in CE Mark countries » 08:10
12/06/21
12/06
08:10
12/06/21
08:10
RHHBY

Roche

$49.35 /

-0.165 (-0.33%)

Roche announced its plans…

Roche announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the beginning of January. Roche also intends to file for Emergency Use Authorization to the U.S. Food and Drug Administration in early 2022. Thomas Schinecker, CEO of Roche Diagnostics, stated, "It is critical that healthcare professionals have the ability to quickly know whether a patient has an infection with either SARS-CoV-2 or the flu, especially as the COVID-19 pandemic extends into our flu season. The combination rapid antigen test will help ensure the right decisions are taken by healthcare providers to treat patients and ultimately prevent community spread. The test adds a solution that will be critical to healthcare systems' long-term management of SARS-CoV-2 and seasonal flu, as we transition from today's global health emergency to the endemic phase of tomorrow."

ShowHide Related Items >><<
RHHBY Roche
$49.35 /

-0.165 (-0.33%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
RHHBY Roche
$49.35 /

-0.165 (-0.33%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

RHHBY Roche
$49.35 /

-0.165 (-0.33%)

Downgrade
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas » 05:33
12/06/21
12/06
05:33
12/06/21
05:33
NVS

Novartis

$79.99 /

+0.03 (+0.04%)

Exane BNP Paribas analyst…

Exane BNP Paribas analyst Richard Parkes downgraded Novartis to Neutral from Outperform with an CHF 85 price target.

ShowHide Related Items >><<
NVS Novartis
$79.99 /

+0.03 (+0.04%)

NVS Novartis
$79.99 /

+0.03 (+0.04%)

12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
NVS Novartis
$79.99 /

+0.03 (+0.04%)

NVS Novartis
$79.99 /

+0.03 (+0.04%)

NVS Novartis
$79.99 /

+0.03 (+0.04%)

NVS Novartis
$79.99 /

+0.03 (+0.04%)

Friday
Hot Stocks
FDA approves Roche's Rituxan with chemo for child cancers » 10:16
12/03/21
12/03
10:16
12/03/21
10:16
RHHBY

Roche

$49.52 /

+0.375 (+0.76%)

The Food and Drug…

The Food and Drug Administration announced the approval of Rituxan in combination with chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$49.52 /

+0.375 (+0.76%)

RHHBY Roche
$49.52 /

+0.375 (+0.76%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
RHHBY Roche
$49.52 /

+0.375 (+0.76%)

RHHBY Roche
$49.52 /

+0.375 (+0.76%)

RHHBY Roche
$49.52 /

+0.375 (+0.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.